LRIG1 levels in chronic rhinosinusitis with nasal polyps
Öz
Purpose: Nasal polyps (NPs), usually occurring together with chronic rhinosinusitis (CRS), are benign masses of mucosal origin arising from inflammation. The transmembrane protein known as leucine-rich repeats and immunoglobulin-like domains 1 (Lrig1) is a member of the Lrig family. Lrig1 is frequently expressed in the respiratory tract and epithelial tissues and can inhibit several signaling pathways involved in cell proliferation. The aim of this study was to determine Lrig1 levels in NP tissues of patients with CRS.
Material and Methods: This study included 36 patients with CRS and NPs and 15 patients who underwent rhinoplasty as the control group. The Lrig1 levels of all participants were measured by the ELISA method.
Results: This study revealed that Lrig1 levels were significantly lower in NP tissues than in tissues of the control group. The mean level of Lrig1 of the NP tissues was 22.2 ng/ml, while the mean level of the control group was 28.5 ng/ml. According to the results of ROC analysis, Lrig1 levels have the power to distinguish polyp tissues from control tissues (AUC=0.794). Lrig1 levels were higher in tissues with scores of 4-8 than in tissues with scores of 16-20 based on the results of computed tomography scoring. According to endoscopic evaluations, Lrig1 levels of tissues with scores of 5-8 or 9-11 were relatively lower than those of tissues with scores of 2-4.
Conclusion: Lrig1 levels were found to be decreased in NP tissues. Thus, Lrig1 may be used to confirm the presence of NPs. Lrig1 may also be helpful in NP grading. Increasing the Lrig1 levels in cases of NPs has the potential to become a targetable treatment modality.
Anahtar Kelimeler
Nasal polyps, Lrig1, ELISA, Rhinosinusitis, Nasal polyps, Lrig1, ELISA, Rhinosinusitis
Kaynakça
- 1. Tat TS. Omalizumab is effective in nasal polyposis with or without asthma, a real-life study. World Allergy Organ J. 2022;15:100670.
- 2. Aldajani A, Alroqi A, Alromaih S, Aloulah MO, Alsaleh S. Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review. Am J Otolaryngol. 2022;43:103615.
- 3. Benjamin MR, Stevens WW, Li N,Bose S, Grammer LC, Kern RC et al. Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting. J Allergy Clin Immunol Pract. 2019;7:1010-1016.
- 4. Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJT et al. Suppression of the negative regulator lrig1 contributes to erbb2 overexpression in breast cancer. Cancer Res. 2008;68:8286-94.
- 5. Jensen KB, Watt FM. Single-cell expression profiling of human epidermal stem and transit-amplifying cells: lrig1 is a regulator of stem cell quiescence. Proc Natl Acad Sci U S A. 2006;103:11958-963.
- 6. Jensen KB , Collins CA, Nascimento E, Tan DW, Frye M, Itami S et al. Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell. 2009;4:427-39.
- 7. Lu L, Teixeira VH, Yuan Z, Graham TA, Endesfelder D, Kolluri K et al. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development. J Pathol. 2013;229:608-20.
- 8. Linke R, Pries R, Könnecke M, Bruchhage KL, Böscke R, Gebhard M et al. The MEK1/2–ERK1/2 pathway is activated in chronic rhinosinusitis with nasal polyps. Arch Immunol Ther Exp (Warsz). 2014;62:217-29.
- 9. Li W, Zhou Y. Lrig1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial–mesenchymal transition. Biosci Rep. 2019;39.
- 10. Klimek L, Koennecke M, Mullol J, Hellings P W, Wang D Y, Fokkenset W et al. A possible role of stem cells in nasal polyposis. Allergy. 2017;72:1868-73.
